ANIP vs CAI: fair value comparison
ANI Pharmaceuticals, Inc. and Caris Life Sciences, Inc. · Updated 2026-10-19
CAI's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, ANIP currently ranks higher by quality score.
| ANIP | CAI | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $72.29 | $30.56 |
| 12-month range | $70.16–$94.48 | $14.55–$32.27 |
| Rank by discount to fair value | #7 of 108 Healthcare | — |
| Rank by quality score | #23 of 301 Healthcare | #24 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ANIP fair value analysis · CAI fair value analysis